RAPT Therapeutics Reports Third Quarter 2024 Financial Results

$RAPT
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $RAPT alert in real time by email

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and nine months ended September 30, 2024.

Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Third Quarter Ended September 30, 2024

Net loss for the third quarter of 2024 was $18.4 million, compared to $31.4 million for the third quarter of 2023.

Research and development expenses for the third quarter of 2024 were $13.3 million, compared to $27.0 million for the same period in 2023. The decrease in research and development expenses was primarily due to lower development costs related to zelnecirnon, tivumecirnon and early stage programs, as well as decreased expenses for personnel, consultants and lab supplies.

General and administrative expenses for the third quarter of 2024 were $6.4 million, compared to $6.9 million for the same period in 2023. The decrease in general and administrative expenses was primarily due to decreased expenses for personnel, consultants and insurance premiums, partially offset by increases in expenses for non-cash stock-based compensation and facilities.

On July 16, 2024, the Company's board of directors approved a reduction of the Company's workforce to conserve cash resources. The workforce reduction affected 47 people, or approximately 40% of the Company's headcount. The Company incurred $0.9 million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance payments, benefits and related costs. The Company completed the workforce reduction plan and all the related cash payments during the third quarter ended September 30, 2024.

Nine Months Ended September 30, 2024

Net loss for the nine months ended September 30, 2024 was $76.6 million, compared to $85.9 million for the same period in 2023.

Research and development expenses for the nine months ended September 30, 2024 were $60.8 million, compared to $74.2 million for the same period in 2023. The decrease in research and development expenses was primarily due to decreases in development costs related to zelnecirnon, tivumecirnon and early-stage programs, as well as lab supplies, partially offset by increased expenses for personnel, consultants, facilities and non-cash stock-based compensation.

General and administrative expenses for the nine months ended September 30, 2024 were $20.9 million, compared to $19.6 million for the same period in 2023. The increase in general and administrative expenses was primarily due to increased expenses for personnel, non-cash stock-based compensation and facilities, partially offset by decreases in expenses for consultants and insurance premiums.

As of September 30, 2024, the Company had cash and cash equivalents and marketable securities of $97.9 million.

About RAPT Therapeutics, Inc.

RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, zelnecirnon (RPT193) and tivumecirnon (FLX475), each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "estimates," "expects," "will" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements, except as required by law.

RAPT Media Contact:

Aljanae Reynolds

areynolds@wheelhouselsa.com

RAPT Investor Contact:

Sylvia Wheeler

swheeler@wheelhouselsa.com



RAPT THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share per share data)

(Unaudited)



  Three Months

Ended


September 30,
  Three Months

Ended


September 30,
  Nine Months

Ended


September 30,
  Nine Months

Ended


September 30,
 
  2024  2023  2024  2023 
Operating expenses:            
Research and development  13,340   27,022   60,761   74,238 
General and administrative  6,448   6,897   20,875   19,607 
Total operating expenses  19,788   33,919   81,636   93,845 
Loss from operations  (19,788)  (33,919)  (81,636)  (93,845)
Other income, net  1,356   2,548   5,020   7,923 
Net loss $(18,432) $(31,371) $(76,616) $(85,922)
Other comprehensive income (loss):            
Foreign currency translation loss           (655)
Unrealized gain on marketable securities  154   59   4   560 
Total comprehensive loss $(18,278) $(31,312) $(76,612) $(86,017)
Net loss per share, basic and diluted $(0.47) $(0.82) $(1.97) $(2.24)
Weighted average number of shares used in computing

net loss per share, basic and diluted
  38,903,476   38,358,032   38,800,528   38,322,773 





RAPT THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands)



  September 30,

2024
  December 31,

2023
 
Assets (Unaudited)  (1)  
Current assets:      
Cash and cash equivalents $37,900  $47,478  
Marketable securities  60,005   111,384  
Prepaid expenses and other current assets  4,693   2,920  
Total current assets  102,598   161,782  
Property and equipment, net  1,653   2,448  
Operating lease right-of-use assets  3,825   5,228  
Other assets  389   3,871  
Total assets $108,465  $173,329  
Liabilities and stockholders' equity      
Current liabilities:      
Accounts payable $1,380  $5,176  
Accrued expenses  6,398   14,103  
Operating lease liabilities, current  2,523   2,448  
Other current liabilities  61   109  
Total current liabilities  10,362   21,836  
Operating lease liabilities, non-current  2,597   4,458  
Total liabilities  12,959   26,294  
Commitments      
Stockholders' equity:      
Preferred stock       
Common stock  3   3  
Additional paid-in capital  656,694   631,611  
Accumulated other comprehensive gain  107   103  
Accumulated deficit  (561,298)  (484,682) 
Total stockholders' equity  95,506   147,035  
Total liabilities and stockholders' equity $108,465  $173,329  



(1) The consolidated balance sheet for December 31, 2023 has been derived from audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.





Primary Logo

Get the next $RAPT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RAPT

DatePrice TargetRatingAnalyst
12/26/2024$10.00Neutral → Buy
H.C. Wainwright
11/13/2024$7.00 → $2.00Buy → Hold
Stifel
11/11/2024$8.00 → $2.00Overweight → Neutral
Piper Sandler
11/11/2024Neutral → Underweight
JP Morgan
5/14/2024Outperform → Peer Perform
Wolfe Research
5/10/2024Buy → Neutral
Guggenheim
5/10/2024$13.00 → $4.00Overweight → Equal Weight
Barclays
2/22/2024$61.00 → $10.00Buy → Neutral
UBS
More analyst ratings

$RAPT
Press Releases

Fastest customizable press release news feed in the world

See more
  • RAPT Therapeutics to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2025 at 3:40 p.m. ET Barclays 27th Annual Global Healthcare Conference – Fireside chat on Wednesday, March 12, 2025 at 10:30 a.m. ET To access the live webcasts or subsequent archived recor

    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company") is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. "Our focus for 2025 will be on advancing development of RPT904, a novel, potential best-in-class option to treat the large and underserved population of patients suffering from food allergy and chronic spontaneous urticaria," said Brian Wong, President and CEO of RAPT. "We belie

    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time. To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-pres

    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RAPT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RAPT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RAPT
SEC Filings

See more

$RAPT
Leadership Updates

Live Leadership Updates

See more
  • RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

    $CTNM
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

    SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations. "I am delighted to announce the addition of Nipun to the RAPT leadership team and welcome his wealth of experience in small molecule product development and commercial manufacturing," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeu

    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel

    SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Michael Listgarten as General Counsel. "I'm excited to welcome Michael to the RAPT leadership team," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "As we advance from development toward potential commercialization, Michael's deep legal expertise and organizational leadership experience from a broad spectrum of biopharmaceutica

    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RAPT
Financials

Live finance-specific insights

See more
  • RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

    - RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patient

    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

    - RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company's Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. The company expects to receive a formal clinical hold letter from

    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

    - Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut off - Confirmed ORR of 50% in patients with PD-L1 high expression (TPS ≥50%) and 38% in patients with PD-L1 low expression (TPS 1-49%) - RAPT to host webcast conference call today at 10:00 am PT SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with s

    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RAPT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more